ClinicalTrials.gg
RecruitingNCT06893510Updated Jun 10, 2026

Virtual Reality-Based and Face-to-Face Relaxation Programs in Pregnant Women With Preeclampsia

An interventional study of Virtual Reality Based Progressive Muscle Relaxation and Face-to-Face Progressive Muscle Relaxation in Pre-Eclampsia, Maternal Health and Relaxation, sponsored by Istanbul University - Cerrahpasa. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Istanbul University - Cerrahpasa · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Pre-Eclampsia with a site in Turkey — 11 open to participants now, 11 under way, none of them phase 3. Pre-Eclampsia · Turkey.

Planned enrollment
5th of 19
96 · median 84
Started
2025
with 4 others
No phase
17 of 50
5 open now
Primary completion
2026-09
later than 8 of 10 live
Registered
40th of 50
by date
Lead sponsor
5 of 50
Istanbul University - Cerrahpasa

Among the 50 studies in Pre-Eclampsia with a site in Turkey, this one is the 5th largest by planned enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2025, is one of 17 with no phase, reaches primary completion later than 8 of the 10 other live ones, and was the 40th registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

11 of the 50 studies in Pre-Eclampsia with a site in Turkey are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Pre-Eclampsia with a site in Turkey, or all of them as a file.
02

Study summary

Preeclampsia, affecting 2-8% of pregnancies globally, is a leading hypertensive disorder in pregnancy. It is clinically characterized by elevated blood pressure (≥140/90 mmHg) after the 20th gestational week, often accompanied by proteinuria and systemic complications such as thrombocytopenia, liver dysfunction, and cerebral symptoms. This condition poses significant risks for both maternal and fetal health, increasing the likelihood of organ damage, preterm birth, and long-term cardiovascular and neurodevelopmental complications. Non-pharmacological interventions, including relaxation techniques, have been explored for symptom management. Progressive muscle relaxation (PMR) has shown efficacy in reducing stress, anxiety, and blood pressure. Recently, virtual reality (VR)-based relaxation techniques have gained attention for enhancing stress relief and improving health outcomes. This study aims to compare the effects of VR-based PMR with in-person PMR on maternal and fetal outcomes in preeclamptic pregnancies.

03

Conditions studied

  • Pre-Eclampsia
  • Maternal Health
  • Relaxation
  • Virtual Reality
  • Fetal Monitoring

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized with a diagnosis of preeclampsia.
  • Gestational age ≥26 weeks.
  • 18 years or older.
  • Singleton and viable pregnancy.
  • Willing to participate in the study voluntarily.

Exclusion criteria

Exclusion Criteria:

  • Multiple pregnancy.
  • Pregnancy achieved through assisted reproductive technologies.
  • Hearing or vision impairment in the pregnant individual.
  • Fetal distress requiring emergency intervention.
  • HELLP Syndrome or Eclampsia.
  • History of vertigo.

Withdrawal Criteria:

  • Cases where live birth does not occur.
  • Participants who voluntarily withdraw from the study.
  • Participants whose general health condition deteriorates during the intervention.
  • Participants experiencing side effects from virtual reality headset use (e.g., dizziness, nausea, headache).
  • Participants who do not practice progressive muscle relaxation at least once a week after the intervention.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Face-to-Face Progressive Muscle Relaxation Group (F2F-PMRG)

    Participants in this group will engage in 15-minute progressive muscle relaxation (PMR) exercises guided by the researcher for three consecutive days (once per day). To promote continued practice, participants will receive an audio recording of the PMR session, narrated by the researcher. After the initial three supervised sessions, they will be asked to listen to this recording twice a week and log their practice on a provided tracking sheet. The researcher will follow up with participants via phone calls to monitor compliance.

    Other: Face-to-Face Progressive Muscle Relaxation

  • Experimental
    Virtual Reality Progressive Muscle Relaxation Group (VR-PMRG)

    Participants will undergo 15-minute VR-assisted PMR sessions for three consecutive days (once per day) under the researcher's supervision. During the VR sessions, participants will be exposed to relaxing nature scenes and sounds while simultaneously engaging in researcher-guided progressive muscle relaxation (PMR) exercises. After the initial three sessions, participants will receive an audio recording of the PMR session and will be instructed to listen to it twice a week, logging their sessions. The researcher will conduct phone follow-ups to ensure adherence.

    Other: Virtual Reality Based Progressive Muscle Relaxation

  • No intervention
    Control Group

    Participants in the control group will not receive any relaxation intervention and will continue their usual daily routines.

Interventions

  • OtherVirtual Reality Based Progressive Muscle Relaxation

    Participants engage in progressive muscle relaxation exercises using a virtual reality headset that provides immersive visual and auditory relaxation content. Sessions are conducted under researcher supervision, followed by self-guided practice using an audio recording.

  • OtherFace-to-Face Progressive Muscle Relaxation

    Participants practice progressive muscle relaxation exercises in a traditional face-to-face setting, guided by a researcher. Initial supervised sessions are complemented by self-guided practice using an audio recording.

06

What researchers measure

Primary outcomes

  1. Descriptive Information Form

    A researcher-developed questionnaire designed to collect sociodemographic and obstetric data based on the literature.

    Time frame: Day 1 (Baseline, Pre-Intervention)

  2. Maternal-Fetal Outcomes Follow-up Form

    Tracked using a researcher-developed follow-up form, including maternal vital signs and Non-Stress Test (NST) parameters.

    Time frame: Day 1 (Baseline, Pre-Intervention), Day 2 and 3 (Post-Intervention for intervention groups, routine monitoring for the control group)

  3. Beck Anxiety Inventory (BAI)

    Developed by Beck, Steer, Epstein, and Brown in 1988 and adapted into Turkish by Ulusoy et al. in 1998, this 21-item Likert-type scale measures anxiety levels. Each item is scored between 0 and 3, with total scores ranging from 0 to 63. Higher scores indicate higher levels of anxiety. The Turkish version has a Cronbach's alpha of 0.93, indicating high internal consistency. Factor analysis suggests two subscales: Subjective Symptoms and Somatic Symptoms.

    Time frame: Day 1 (Baseline, before intervention for intervention groups, before routine assessment for control group) and Day 3 (Post-intervention for intervention groups, after routine assessment for control group).

  4. Prenatal Comfort Scale (PCS)

    Originally developed by Takeishi et al. in 2011 in Japan and later revised by Nakamura et al. in 2015 to a 15-item version, this scale measures prenatal comfort across five subscales: Partner's Role in Fatherhood, Fetal Interaction, Social Support, Maternal Role Adaptation, and Awareness of Pregnancy Changes. The 6-point Likert-type scale ranges from 0 (strongly disagree) to 5 (strongly agree), with higher scores indicating higher comfort levels. The scale has a Cronbach's alpha of 0.95 in the original study and 0.82 in the Turkish adaptation.

    Time frame: Day 1 (Baseline, before intervention for intervention groups, before routine assessment for control group) and Day 3 (Post-intervention for intervention groups, after routine assessment for control group).

  5. Heart Rate Variability (HRV) Measurement via Photoplethysmography (PPG)

    A non-invasive test used to assess physiological stress levels by measuring heart rate variability (HRV) through a photoplethysmography (PPG) sensor placed on the fingertip.

    Time frame: Day 1 (Baseline, before the relaxation intervention) and Day 3 (Post-intervention, after the relaxation session).

  6. Satisfaction Evaluation Form (VAS)

    A researcher-developed form assessing participants' overall satisfaction with the intervention, perceived anxiety and stress reduction, and general experience. (only for intervention groups)

    Time frame: Day 3 (Post-Intervention)

  7. Edinburgh Postpartum Depression Scale (EPDS)

    eveloped by Cox et al. in 1987 and adapted into Turkish by Engindeniz et al. in 1996, this 10-item, 4-point Likert-type self-report scale assesses postpartum depression risk. Scores range from 0 to 30, with a cut-off point of 13. Internal consistency in the Turkish adaptation is 0.79, with a sensitivity of 0.84 and specificity of 0.88.

    Time frame: Up to 4-6 weeks postpartum (via phone follow-up)

  8. Postpartum Evaluation Form

    A researcher-developed form assessing delivery type, maternal and neonatal health parameters, and newborn evaluations based on literature

    Time frame: Up to 4-6 weeks postpartum (via phone follow-up)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020 Jun;135(6):e237-e260. doi: 10.1097/AOG.0000000000003891. PubMed 32443079 ↗
  • Bell IH, Nicholas J, Alvarez-Jimenez M, Thompson A, Valmaggia L. Virtual reality as a clinical tool in mental health research and practice . Dialogues Clin Neurosci. 2020 Jun;22(2):169-177. doi: 10.31887/DCNS.2020.22.2/lvalmaggia. PubMed 32699517 ↗
  • Bernstein, D. A., Borkovec, T. D., & Hazlett-Stevens, H. (2000). New directions in progressive relaxation training: A guidebook for helping professionals. Praeger Publishing.
  • Chuang LL, Lin LC, Cheng PJ, Chen CH, Wu SC, Chang CL. The effectiveness of a relaxation training program for women with preterm labour on pregnancy outcomes: a controlled clinical trial. Int J Nurs Stud. 2012 Mar;49(3):257-64. doi: 10.1016/j.ijnurstu.2011.09.007. Epub 2011 Oct 2. PubMed 21968280 ↗
  • Dominguez-Solis E, Lima-Serrano M, Lima-Rodriguez JS. Non-pharmacological interventions to reduce anxiety in pregnancy, labour and postpartum: A systematic review. Midwifery. 2021 Nov;102:103126. doi: 10.1016/j.midw.2021.103126. Epub 2021 Aug 14. PubMed 34464836 ↗
  • Escobar-Bermudez A, Bejarano-Beltran MP. Experiences of women with preeclampsia in an Obstetric Intensive Care Unit in Colombia. Enferm Clin (Engl Ed). 2021 May-Jun;31(3):166-174. doi: 10.1016/j.enfcli.2020.11.003. Epub 2021 Jan 9. English, Spanish. PubMed 33436348 ↗
  • Estrella-Juarez F, Requena-Mullor M, Garcia-Gonzalez J, Lopez-Villen A, Alarcon-Rodriguez R. Effect of Virtual Reality and Music Therapy on the Physiologic Parameters of Pregnant Women and Fetuses and on Anxiety Levels: A Randomized Controlled Trial. J Midwifery Womens Health. 2023 Jan;68(1):35-43. doi: 10.1111/jmwh.13413. Epub 2022 Nov 16. PubMed 36383473 ↗
  • Ferguson C, Davidson PM, Scott PJ, Jackson D, Hickman LD. Augmented reality, virtual reality and gaming: an integral part of nursing. Contemp Nurse. 2015;51(1):1-4. doi: 10.1080/10376178.2015.1130360. Epub 2016 Jan 14. No abstract available. PubMed 26678947 ↗
  • Folk DM. Hypertensive Disorders of Pregnancy: Overview and Current Recommendations. J Midwifery Womens Health. 2018 May;63(3):289-300. doi: 10.1111/jmwh.12725. Epub 2018 May 15. PubMed 29764001 ↗
  • Hajesmaeel-Gohari S, Sarpourian F, Shafiei E. Virtual reality applications to assist pregnant women: a scoping review. BMC Pregnancy Childbirth. 2021 Mar 25;21(1):249. doi: 10.1186/s12884-021-03725-5. PubMed 33765969 ↗
  • Ioannou A, Papastavrou E, Avraamides MN, Charalambous A. Virtual Reality and Symptoms Management of Anxiety, Depression, Fatigue, and Pain: A Systematic Review. SAGE Open Nurs. 2020 Aug 27;6:2377960820936163. doi: 10.1177/2377960820936163. eCollection 2020 Jan-Dec. PubMed 33415290 ↗
  • Machado MSR, Bertagnolli TV, Veiga ECA, Ferreira CJH, Duarte G, Machado JSR, Carvalho R. Multiprofessional care promotes of quality of life in pregnant women with preeclampsia: a cross-sectional study. Clinics (Sao Paulo). 2020 Oct 26;75:e1951. doi: 10.6061/clinics/2020/e1951. eCollection 2020. PubMed 33146357 ↗
  • Severi FM, Prattichizzo D, Casarosa E, Barbagli F, Ferretti C, Altomare A, Vicino A, Petraglia F. Virtual fetal touch through a haptic interface decreases maternal anxiety and salivary cortisol. J Soc Gynecol Investig. 2005 Jan;12(1):37-40. doi: 10.1016/j.jsgi.2004.07.006. PubMed 15629669 ↗
  • Son H, Ross A, Mendoza-Tirado E, Lee LJ. Virtual Reality in Clinical Practice and Research: Viewpoint on Novel Applications for Nursing. JMIR Nurs. 2022 Mar 16;5(1):e34036. doi: 10.2196/34036. PubMed 35293870 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will be stored in an online database (e.g., Mendeley). Data will be available upon request after the study results are published by the researchers.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2026, 11 months after the start.

Of 172 non-industry interventional studies with no phase under Pre-Eclampsia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 11 months is below that.

Counting every sponsor, half of 177 studies reached it within 24 months; a quarter within 10 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2025
First posted
Mar 25, 2025
StartActual
Sep 8, 2025
Primary completionEst.
Sep 1, 2026
CompletionEst.
Sep 1, 2026
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06893510
Responsible party
Güzin Ünlü Suvari (M.Sc, Ph.D. Student, Istanbul University - Cerrahpasa) — Principal investigator
First posted
Mar 25, 2025
Start date
Sep 8, 2025
Primary completion
Sep 1, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Jun 10, 2026

Study contacts

Güzin Ünlü Suvari, M.Sc.
Contact
guzin.unlu@ogr.iuc.edu.tr
+902165004429
Ergül Aslan, Prof. Dr.
principal investigator · İstanbul University-Cerrahpaşa

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion